HomeCompareRPHCF vs MRK

RPHCF vs MRK: Dividend Comparison 2026

RPHCF yields 1.82% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RPHCF wins by $43.17M in total portfolio value· pulled ahead in Year 3
10 years
RPHCF
RPHCF
● Live price
1.82%
Share price
$15.20
Annual div
$0.28
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$43.23M
Annual income
$39,107,153.37
Full RPHCF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RPHCF vs MRK

📍 RPHCF pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRPHCFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RPHCF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RPHCF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RPHCF
Annual income on $10K today (after 15% tax)
$154.90/yr
After 10yr DRIP, annual income (after tax)
$33,241,080.36/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, RPHCF beats the other by $33,232,751.95/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RPHCF + MRK for your $10,000?

RPHCF: 50%MRK: 50%
100% MRK50/50100% RPHCF
Portfolio after 10yr
$21.64M
Annual income
$19,558,475.76/yr
Blended yield
90.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RPHCF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
5/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RPHCF buys
0
MRK buys
0
No recent congressional trades found for RPHCF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRPHCFMRK
Forward yield1.82%2.76%
Annual dividend / share$0.28$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$43.23M$56.8K
Annual income after 10y$39,107,153.37$9,798.13
Total dividends collected$42.89M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: RPHCF vs MRK ($10,000, DRIP)

YearRPHCF PortfolioRPHCF Income/yrMRK PortfolioMRK Income/yrGap
1$11,064$364.47$11,206$366.19$142.00MRK
2$12,593$753.78$12,650$502.35$57.00MRK
3← crossover$15,078$1,603.54$14,407$694.19+$671.00RPHCF
4$19,722$3,588.75$16,585$967.82+$3.1KRPHCF
5$29,877$8,774.08$19,342$1,363.89+$10.5KRPHCF
6$56,812$24,844.41$22,913$1,947.19+$33.9KRPHCF
7$149,094$88,305.24$27,662$2,823.89+$121.4KRPHCF
8$592,694$433,162.94$34,159$4,173.35+$558.5KRPHCF
9$3,852,779$3,218,596.09$43,337$6,308.80+$3.81MRPHCF
10$43,229,627$39,107,153.37$56,776$9,798.13+$43.17MRPHCF

RPHCF vs MRK: Complete Analysis 2026

RPHCFStock

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

Full RPHCF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RPHCF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RPHCF vs SCHDRPHCF vs JEPIRPHCF vs ORPHCF vs KORPHCF vs MAINRPHCF vs JNJRPHCF vs ABBVRPHCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.